Submucosal Lipiodol Injection to Guide Radiotherapy for Esophageal CancerHan Yao, Christian Boukaram and George Rakovich*
George Rakovich, thoracic surgery, University of montreal, Canada
- *Corresponding Author:
- George Rakovich
University of montreal, Canada
E-mail: [email protected]
Received date: July 30, 2014; Accepted date: October 17, 2014; Published date: October 24, 2014
Citation: Yao H, Boukaram C, Rakovich G (2014) Submucosal Lipiodol Injection to Guide Radiotherapy for Esophageal Cancer. J Gastroint Dig Syst 4:230. doi:10.4172/2161-069X.1000230
Copyright: © 2014 Yao H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Radiotherapy for esophageal cancer relies on cross-sectional imaging to identify the entire extent of tumor.
Rarely, the exact limits of the tumor may be radiologically occult. Lipiodol is a contrast agent which has been used
successfully to mark cancers of the bladder and lung for radiotherapy and surgical resection. We report a patient
with an adenocarcinoma of the gastroesophageal junction with tiny tumor implants extending proximally along the
length of the esophagus, which were not visible on standard cross-sectional imaging studies. The proximal extent of
implants was marked endoscopically using a submucosal injection of lipiodol, and this provided for adequate
planning and successful delivery of radiotherapy.